Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares traded lower over the last trading session, losing -23.80% on 05/21/20. The shares fell to a low of $19.0487 before closing at $15.62. Intraday shares traded counted 3.72 million, which was -435.26% lower than its 30-day average trading volume of 694.76K. SNDX’s previous close was $20.50 while the outstanding shares total 34.33M. The firm has a beta of 1.91. The stock’s Relative Strength Index (RSI) is 45.68, with weekly volatility at 12.17% and ATR at 1.84. The SNDX stock’s 52-week price range has touched low of $5.35 and a $21.97 high.
Investors have identified the Biotechnology company Syndax Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $703.74 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Syndax Pharmaceuticals Inc. (SNDX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For SNDX, the company has in raw cash 44.74 million on their books with 0.48 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 104206000 million total, with 18790000 million as their total liabilities.
Potential earnings growth for Syndax Pharmaceuticals Inc. (SNDX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Syndax Pharmaceuticals Inc. recorded a total of 0.38 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.0% coming in sequential stages and their sales for the third quarter reducing by -0.26%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.38 million trying to sell their products during the last quarter, with the result yielding a gross income of 15.48 million. This allows shareholders to hold on to 34.33M with the revenue now reading -0.56 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.51 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.84 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SNDX sounds very interesting.
Is the stock of SNDX attractive?
In related news, Chief Executive Officer, Morrison Briggs bought 12,500 shares of the company’s stock in a transaction that recorded on Feb 04. The purchase was performed at an average price of 8.00, for a total value of 100,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
5 out of 8 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Syndax Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the SNDX stock. The 12-month mean consensus price target for the company’s shares has been set at $20.00.